ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Drug firms pick contract providers

by Rick Mullin
April 9, 2018 | APPEARED IN VOLUME 96, ISSUE 15

Alnylam Pharmaceuticals has selected Agilent Technologies to manufacture the active pharmaceutical ingredient for its RNAi therapeutic patisiran. Patisiran is an oligonucleotide targeting transthyretin for the treatment of the rare disease ATTR amyloidosis. Meanwhile, Scancell Holdings has signed up PolyPeptide Group, a contract manufacturer of therapeutic peptides, to make a peptide conjugate to Amplivant, an immuno-oncology drug Scancell is developing.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment